Form 4: Eton Pharma CEO Discloses Tax-Related Stock Sale

Eton Pharmaceuticals' President and CEO, Sean Brynjelsen, reported the disposition of 6,732 common shares to cover tax obligations from restricted stock unit vesting.

Summary

• Sean Brynjelsen, President & CEO, Director, and 10% Owner of Eton Pharmaceuticals, Inc. (ETON), reported a transaction on December 12, 2025.
• The transaction involved the disposition of 6,732 shares of common stock.
• These shares were withheld by the Issuer to satisfy applicable withholding taxes upon the vesting of restricted stock units.
• The shares were disposed of at a weighted average price of $16.83 per share, with individual trades ranging from $16.66 to $16.98.
• Following this transaction, Sean Brynjelsen beneficially owns 2,894,281 shares of common stock directly.
• The transaction was made pursuant to a Rule 10b5-1(c) plan.

Sentiment

Score: 5

Explanation: The transaction is a routine, non-discretionary event for tax withholding upon RSU vesting, which is a neutral event in terms of company performance or strategic direction.

Positives

• The transaction was non-discretionary, related to tax obligations from RSU vesting, indicating a standard compensation event rather than a voluntary sale for other reasons.
• The transaction was executed under a Rule 10b5-1(c) plan, which provides an affirmative defense against insider trading allegations.

Negatives

• A reduction in direct beneficial ownership by 6,732 shares, although for tax purposes.

Future Outlook

There are no forward-looking statements or guidance provided.

Industry Context

This disclosure is a routine insider transaction for tax purposes and does not provide specific insights into broader industry trends or competitive landscape.

Related Party Transactions

• Disposition of 6,732 common shares by CEO Sean Brynjelsen to the issuer for tax withholding purposes related to RSU vesting.

Stakeholder Impact

• Minimal direct impact on shareholders as this is a routine, non-discretionary tax-related transaction by an insider.
• No direct impact on employees, customers, suppliers, or creditors.

Key Dates

Recommendation

This Form 4 filing details a routine, non-discretionary transaction by the CEO to cover tax obligations from restricted stock unit vesting. It does not reflect a change in the company's fundamentals, strategic direction, or the insider's discretionary view on the stock's future performance. Therefore, it provides no new information to warrant a change in investment recommendation based solely on this disclosure.

Keywords

Eton Pharmaceuticals, ETON, Sean Brynjelsen, Form 4, Insider Transaction, Stock Sale, Restricted Stock Units, Tax Withholding, Beneficial Ownership, CEO, Director, 10% Owner, Pharmaceuticals